The U.S. Food and Drug Administration has approved the use of Afrezza, an inhalable, fast-acting insulin powder that comes in single-use cartridges delivered through an inhaler named Dreamboat.
Earlier, in April, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 1 to recommend that Afrezza (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes.
Read more